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Summary The cytoxicity of both intercalating (m-AMSA) and non-intercalating (VP16, VM26)
topoisomerase II-targeting drugs is thought to occur via trapping DNA topoisomerase II on DNA in the form
of cleavable complexes. First, analysis of cleavable complexes (detected as DNA double-strand breaks) by
pulsed-field gel electrophoresis confirmed the correlation between cleavable complex formation and cytotox-
icity of three topoisomerase-targeting drugs in HeLa S3 cells (the order of effects being VM26> m-
AMSA>VP16). In contrast to many antineoplastic agents, hyperthermic treatments were found to protect
cells against the toxicity of all three topoisomerase II drugs. Hyperthermia treatment does not alter drug
accumulation but reduces the ability of the drug-topoisomerase II complex to form the cleavable complexes.
Nuclear protein aggregation induced by heat at the sites of topoisomerase II-DNA interaction may explain
such an effect. In thermotolerant cells, the toxic effects of VP16 but not m-AMSA were reduced. For both
drugs, however, the status of thermotolerance did not affect cleavable complex formation by the drugs. Thus,
protection against VP-16 toxicity seems not to be associated with heat-induced activation of the P-gp 170
pump or altered topoisomerase II-DNA interactions. Rather, a protective (heat shock protein mediated?)
mechanism against non-intercalating topoisomerase II drugs seems to occur at a stage after DNA-drug
interaction. Finally, heat treatment before topoisomerase II drug treatment reduced toxicity and cleavable
complex formation in thermotolerant cells to about the same extent as in non-tolerant cells, consistent with the
presumption of nuclear protein aggregation being responsible for this effect.
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Hyperthermia is a powerful tool to enhance the cell killing
effects of radiation (Konings, 1987) and many anti-neoplastic
agents (Engelhardt, 1987). However, heat pretreatment leads
to a reduction in the toxic action of some drugs. Preheating
causes resistance to daunorubicin (Mizuno et al., 1980), dox-
orubicin (Rice and Hahn, 1987) and m-AMSA (Kampinga et
al., 1989a). Interestingly, the putative target ofall these drugs
is DNA topoisomerase II (Wang, 1985).
It has been shown that the reduction in cytotoxicity of
m-AMSA resulting from preheating cells is not due to heat-
altered drug permeability (Kampinga et al., 1989a) or to
thermal inactivation of the topoisomerase II enzyme (Kamp-
inga et al., 1989a; Warters and Barrows, 1994). Reduced
toxicity is accompanied by a reduction in topoisomerase
II-mediated DNA breakage (cleavable complex formation)
(Kampinga et al., 1989a). Since the topoisomerase II
inhibitors used in these studies are all DNA intercalators
(Wang, 1985), and since heat affects intercalator-induced
changes in DNA supercoiling (Kampinga et al., 1988, 1989b),
the reduced toxicity after heat may result from altered DNA
intercalation ofthe drug. On the other hand, the effects could
be due to a reduced accessibility of the topoisomerase II
consensus sequences (= topoisomerase II cleavage sites).
These sites are enriched in DNA found in close association
with the nuclear matrix, called matrix-associated regions
(MARs; Mirkovitch et al., 1984; Cockerill and Garrard,
1986; Darby et al., 1986; Gasser and Laemmli, 1986;
Udvardy et al., 1986). Hyperthermia has been shown to
cause an insolubilisation (aggregation) of nuclear (matrix)
proteins (for reviews see Laszlo, 1992; Kampinga, 1993). This
might reduce the accessibility of the topoisomerase II
cleavage sites at the MARs and thereby the toxicity of
topoisomerase II drugs after heat treatment. To distinguish
between these possibilities, the interaction of heat and non-
intercalating topoisomerase II drugs, VP16 and VM26, was
studied in the current report.
Finally, the effect of thermotolerance on topoisomerase II
drug toxicity was evaluated. First, elevated heat shock pro-
tein (hsp) expression, as found in thermotolerant cells, has
been suggested to be responsible for resistance to topoiso-
merase II drugs. A mutant, heat-resistant cell line (3012) in
which only hsc70 was elevated was found to be resistant to
VM26 (Li, 1987). Also, modulation of the levels of hsp27 in
gene transfection expcriments showed a good correlation
between hsp27 expression and doxorubicin resistance (Huot
et al., 1991; Oesterreich et al., 1993). Secondly, being resis-
tant to heat toxicity, it may be expected that thermotolerant
cells show a reduced heat (protection) effect on topoisomer-
ase II drug sensitivity. To test this, the sensitivity of ther-
motolerant cells (with elevated hsp expression) towards heat
and topoisomerase II drug treatments was compared with the
sensitivity of non-tolerant cells.
Materials and methods
Materials
HeLa S3 cells were used in this study and grown in suspen-
sion in Joklik minimum essential medium (MEM) (Flow,
Irvine, UK) containing 10% fetal bovine serum (Gibco,
Paisley, UK). The cultures were in exponential growth
(doubling times about 26 h) and more than 95% of the cells
excluded trypan blue.
m-AMSA (4'-(9'-acridinylamino)-methanesulphon-m-aniside;
NCIL, USA) was a generous gift from Dr JL Roti Roti
(Washington University, St Louis, MO, USA). VP16 and
VM26 were generously provided by Bristol Meyers (Walling-
ford, USA). All drugs were dissolved in 100% dimethylsul-
phoxide (DMSO) at a concentration of 10 mm and frozen at
- 20°C until use. All other standard laboratory chemicals
were purchased from Sigma (St Louis, MO, USA) or Merck
(Darmstadt, Germany).
Conditionsfor hyperthermia and drug treatment
Hyperthermia was induced in precision water baths (± 0.1C)
under conditions of gentle agitation. Thermotolerance was
induced by a heat treatment of 15 min at 44°C, followed by
5 h development at 37°C. Directly after the heat treatments,
the cells were added to a 10-fold concentrated drug solution
in complete medium of the desired concentration and treated
with the drug at 37°C. Drug-induced toxicity (as well as
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drug-induced break formation) saturates rapidly in time at
37°C (< 15 min) (Kampinga et al., 1989a, data not shown):
30 min treatment was therefore used in all experiments.
Subsequently, samples were processed for the determination
of cell survival (clonogenic ability and MTT) or for deter-
mination of cleavable complex (= DNA double-strand
break) formation using clamped homogeneous electric field
(CHEF) electrophoresis.
Determination ofdrug toxicity
For drug toxicity testing two different assays were compared.
The colony-forming ability of the cells was tested by applying
0.1 ml of an appropriately diluted sample to 0.5% soft-agar
plates as described previously (Jorritsma and Konings, 1983).
The results of this assay were compared with those obtained
with the more rapid microculture tetrazolium (MTT; Car-
michael et al., 1987) assay with potential use in the clinic for
rapid screening ofcells obtained from patients. In short, after
a
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the various heat treatments 3750 cells were plated in each
well of a 96-well microculture plate (Nunc, Life Tech-
nologies, Paisley, UK) and incubated with the various drugs
for 30 min at 37°C (prolonged exposure up to 60min did not
further enhance drug toxicity; data not shown). After the
incubation, the cells were washed three times by adding
150ftl ofmedium, centrifuging the microtitre plate for 10 min
at 200g and removing the extra medium. After a culture
period of 4 days, 20ftl of MTT solution (5 mg of MTT per
ml of phosphate-buffered saline) was added to each well for
3.75 h. Thereafter, the plates were centrifuged for 15 min at
200g, after which the supernatant was carefully removed. A
200 volume ytL of DMSO (100%) was used to dissolve the
formazan crystals. Absorption at 520 nm was measured using
a scanning microtitre well spectrophotometer (Titertek Mul-
tiskan, Flow Laboratories). Percentage cell survival was cal-
culated by dividing the mean absorption of the test samples
minus the background extinction (medium without cells) by
the mean absorbance of the untreated sample minus the
background extinction.
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Figure 1 Effect of hyperthermia treatment for 15 min at 45°C on the cytotoxicity of topoisomerase 11-targeting drugs: comparison
of the clonogenic (a-c) and MTT assays (d-f). HeLa S3 cells were treated for 30 min at 37°C with the m-AMSA (a and d), VP16
(b and e) or VM26 (c and f). Cells were left either unheated (C, 0) or were treated at 45°C for 15 min (A) before the drug
treatment. Points represent the mean values ± standard errors of the mean of at least three independent experiments.
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Drug-induced break formation was measured by pulsed-field
gelelectrophoresis (PFGE). This method, in the form of
CHEF electrophoresis, detects DNA fragmentation on the
basis of the formation of DNA double-strand breaks only
and has been described in detail by Blocher and co-workers
(Blocher et al., 1989; Blocher and Kunhi, 1990). It was used
with slight modification, applying image analysis-based
fluorescent detection as described previously (Rosemann et
al., 1993). In short, cells were imbedded in agarose
immediately after heat treatment and incubated with the
drugs for 30 min at 37°C in 96-well microtitre plates.
Thereafter, the cells were immediately lysed and treated with
proteinase K and RNAse. CHEF electrophoresis (Bio-Rad)
was carried out using 1% chromosomal grade agarose gels
(Bio-Rad) using 75 min pulses at 40 V for 25 h. After the
run, the DNA was stained with ethidium bromide. The frac-
tion of DNA fragmented was determined by image analysis
as described previously (Rosemann et al., 1993).
Results
In a previous study (Kampinga et al., 1989a), it was shown
that preheating of both EAT and HeLa S3 cells led to a
protection against the toxicity of the DNA-intercalating
topoisomerase drug m-AMSA. This was confirmed in this
study: both in the clonogenic assay (Figure la) and in the
MTT assay (Figure Id), heating at 45'C for 15 min
a
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immediately before the drug treatment reduced the killing
efficacy of the drug. As can be seen in Figure 1, a reduction
in toxicity was also found for the non-intercalative
topoisomerase II inhibitors VP16 and VM26. Heat-induced
protection against drug toxicity was less for the non-
intercalators than for m-AMSA (Figure 1). As can be seen,
the MTT and clonogenic assay yielded quite similar results
and the extent of thermal protection was quite similar for
both assays. Therefore, at least for these set of drugs, the
more rapid and economic MTT assay can be used to study
the combined effects of topoisomerase II drugs and heat.
HeLa S3 cells made thermotolerant by prior heating
(15 min at 44°C and 5 h at 37'C) were found to have
unaltered sensitivity to m-AMSA compared with non-
tolerant cells (Figure 2a). In contrast, the thermotolerant
cells were clearly more resistant to the non-intercalating
topoisomerase II drug VP16 (Figure 2b). A heat treatment
for 15 min at 45°C immediately before drug treatment still
had a significant protective effect on the sensitivity to both
m-AMSA and VP16 in thermotolerant cells (Figure 2a and
b). For m-AMSA the extent of this effect was similar to that
observed in non-tolerant cells. For VP16, the protective effect
of preheating on drug toxicity was somewhat less in ther-
motolerant cells.
The formation of cleavable complexes (detected as break
formation after dissociation of the protein-drug-DNA
interaction) has often been found to be related to drug
toxicity oftopoisomerase II drugs (Bakic et al., 1986; Glisson
et al., 1986; Rowe et al., 1986; Covey et al., 1988). Here,
PFGE was used to detect double-strand breaks after the
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Figure 2 Effect of thermotolerance on m-AMSA (a) and VP16
(b) toxicity and on the effect of hyperthermia treatment (45°C for
15 min) on the cytotoxicity of these drugs. HeLa S3 cells were left
untreated (C) or made thermotolerant (TT: 15 min at 44°C + 5 h
at 37°C). All cells were subsequently treated for 30 min at 37°C
with m-AMSA (a) or VP16 (b). Control and thermotolerant cells
were left either unheated (C, A; TT, *) or were treated with
heat for 15 min at 45°C (C-HT, *; TT-HT, V) before the drug
treatment. Points represent the mean values ± standard errors of
the mean of at least three independent experiments.
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Figure 3 Comparison of the cytotoxicity of topoisomerase II-
targeting drugs with drug-induced cleavable complex formation.
HeLa S3 cells were treated for 30 min at 37°C with the m-AMSA
(A), VP16 (0) or VM26 (*). Cells were subsequently processed
for cytotoxicity: (a) clonogenic assay and (b) cleavable complex
formation (leading to protein-associated DNA double-strand
breaks that were measured as percentage DNA fragmentation by
PFGE). Points represent the mean values ± standard errors of the
mean of at least three independent experiments.
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various (heat plus) drug treatments. Consistent with the
findings of others (Bakic et al., 1986; Glisson et al., 1986;
Rowe et al., 1986; Covey et al., 1988), it was found that, for
the same concentrations, VM26 was far more potent than
VP16 in inducing protein-associated breaks; m-AMSA
showed an intermediate pattern (Figure 3b). As can be seen,
this reflects the different toxicity of these drugs (Figure 3a).
Drug-induced break formation was attenuated in cells
pretreated with heat; this was true for both m-AMSA and
VP16 (Figure 4), in accordance with the protection seen at
the level of cell survival. In thermotolerant cells, m-AMSA
caused DNA fragmentation to the same extent as in control
cells (Figure Sa), and heating the thermotolerant cells also
reduced m-AMSA-induced DNA fragmentation, all again in
parallel with the patterns seen at the survival level (Figure 2).
For VP16, however, thermotolerant cells again showed DNA
fragmentation patterns indistinguishable from non-tolerant
cells (Figure 5b), in contrast to their resistance to drug-
induced cell death (Figure 2b). When heat preceded VP16
treatment, the same protection against drug-induced DNA
fragmentation was found as in non-tolerant cells (Figures 4
and 5). Thus, drug-induced DNA fragmentation and cell
killing correlated in all cases except for the effect of ther-
motolerance on VP16 sensitivity (with no additional heat).
Discussion
Mechanism of heat protection against topoisomerase II drugs
Heat was shown to be able to potentiate the effect of several
drugs (Engelhardt, 1987), and as such seems a good can-
didate as adjuvant in some chemotherapeutic protocols.
However, pretreatment with heat apparently reduced the kill-
ing efficacy of some drugs, especially those that have been
suggested to act as topoisomerase II poisons (Mizuno et al.,
1980; Rice and Hahn, 1987; Kampinga et al., 1989a). In this
report, it is clearly shown that heat attenuates the effect not
only of DNA-intercalating topoisomerase II drugs (duano-
rubicin and m-AMSA) but also of non-intercalating topoiso-
merase II poisons such as VP16 and VM26. It must thus be
concluded that an altered response to intercalator-induced
DNA supercoiling changes as found after heat (Kampinga et
al., 1989a) is not the major cause of the heat-induced protec-
tion against topoisomerase II poisons. Perhaps unexpectedly,
the heat-induced protection against topoisomerase I1 drug
was seen to a similar extent in thermotolerant cells. Being
resistant to hyperthermia, one might have expected to see less
protection in thermotolerant cells. Thus, the mechanism
underlying the protective effects of heat for topoisomerase II
drug toxicity must be the same in thermotolerant and non-
tolerant cells (see below).
As demonstrated previously, thermal protection against
topoisomerase II drug toxicity is unlikely to be due to
reduced intracellular drug accumulation since permeabilised
cells and non-permeabilised cells show a similar reduction in
cleavable complex formation (Kampinga et al., 1989a). Also,
heat-induced inactivation of the total cellular activity of
topoisomerase II is an unlikely explanation since this enzyme
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Figure 4 Effect of a 15 min, 45'C hyperthermia treatment on
topoisomerase II drug-induced cleavable complex formation.
HeLa S3 cells were treated for 30 min at 37°C with m-AMSA (a)
or VPl6 (b). Cells were either left unheated (C, 0) or were
treated with 45'C heat for 15 min (A) before the, drug treatment.
Cells were subsequently processed for cleavable complex forma-
tion, leading to protein-associated DNA double-strand breaks
that were measured as percentage DNA fragmentation by PFGE.
Points represent the mean values ± standard errors of the mean
of at least two independent experiments.
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Figure 5 Effect of thermotolerance on m-AMSA (a) and VP16
(b) induced cleavable complex formation and on the effect of a
15min, 45°C hyperthermia treatment on the cleavable complex
formation by these drugs. HeLa S3 cells were made ther-
motolerant (TT: 15 min at 44'C + 5 h at 37'C) and subsequently
treated for 30min at 37°C with 10iM m-AMSA (a) or 10LM
VP16 (b). They were left either unheated (C, TT) or were treated
with 45°C heat for 15 min (C-HT, TT-HT) before the drug
treatment. Cleavable complex formation, leading to protein-
associated DNA double-strand breaks was measured as percen-
tage DNA fragmentation by PFGE. The data were corrected for
background DNA fragmentation (approximately 10%). Bars
represent the mean values of at least two independent
experiments.
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seems relatively heat stable (Warters and Barrows, 1994). In
accordance with previous studies (Bakic et al., 1986; Glisson
et al., 1986; Rowe et al., 1986; Covey et al., 1988; Kampinga
et al., 1989a), drug-induced break formation and cytotoxicity
of topoisomerase II drugs were found to be related under all
but one condition (see below). Hyperthermia before drug
treatment decreases the number of cleavable complexes
formed in proportion to the effects on drug toxicity. The heat
protection action is thus related to reduced ability of the
drugs to form cleavable complexes. As proposed before
(Kampinga et al., 1989a), the most likely explanation of this
effect is a heat-induced change in the conformation of the
topoisomerase II site, by decreasing the accessibility of either
the topoisomerase II site for the topoisomerase 11-drug com-
plex or the topoisomerase 1I-DNA complex for the drug.
These interaction sites are known to be located at or near the
control regions of active genes (Riou et al., 1986; Udvardy et
al., 1986) and were found to be identical to the DNA sites
(MARs) that are located at the nuclear matrix (Darby et al.,
1986; Gasser and Laemmli, 1986; Mirkovitch et al., 1986;
Pommier et al., 1991). The MARs are thought to be impor-
tant for the regulation of several DNA processes (Berezney,
1984) including replication, transcription and perhaps also
repair. Thermal denaturation of (nuclear) proteins resulting
in aggregation of usually soluble nuclear proteins (see Kamp-
inga, 1993, for review) with the (insoluble) nuclear matrix
was found to correlate with the inhibitory effect of heat on
m-AMSA toxicity (Kampinga et al., 1989a). This aggregation
also was found to be related to altered DNA-matrix attach-
ment interactions (Warters et al., 1986; Sakkers et al., sub-
mitted). In HeLa S3 cells, the initial aggregation is the same
in thermotolerant cells as in non-tolerant cells (Kampinga et
al., 1987, 1989c), consistent with the observation that thermal
protection against drug toxicity and break formation is about
the same in thermotolerant and non-tolerant cells (Figures 4
and 5). The absence of a significant protective effect when
heat is given after the VP16 and VM26 treatment (data not
shown) is also in favour of an interrelationship between
heat-induced decrement in MAR accessibility by protein agg-
regation and heat protection against drug toxicity: when the
topoisomerase II-DNA complex has formed, heat cannot
alter its toxicity any more and the treatments are additive in
toxicity.
Thermotolerance, hsp and topoisomerase II drugs
With regards to the effect of thermotolerance on topoiso-
merase II drug sensitivity, different results were obtained for
m-AMSA (intercalator) and VP16 (non-intercalator). Where-
as the cells' sensitivity to m-AMSA was not affected by the
state of thermotolerance, thermotolerant cells did show resis-
tance to VP16. Since the cell cycle distribution was not
significantly different for thermotolerant and non-tolerant
cells (Kampinga et al., 1989c; data not shown), this effect
cannot be attributed to cell cycle-specific toxicity of the
topoisomerase II drug. A reduced sensitivity towards non-
intercalating topoisomerase II drugs in thermotolerant cells
has also been observed by Li (1987) and was speculated to be
due to overexpression of hsp, hsc7O in particular. Yet others
(Ciocca et al., 1992) also found that thermotolerance could
result in resistance to intercalating topoisomerase II drugs
such as doxorubicin. Moreover, different levels of hsp27
expression were found to be related to resistance to dox-
orubicin (Huot et al., 1991; Oesterreich et al., 1993). So,
whether the (non)intercalating character of the two drugs is
the reason for the absence/presence of a protective mecha-
nism operating in thermotolerant cells remains obscure.
Another possibility may be found in the observation that the
DNA cleavage pattern as a result of m-AMSA treatment was
different from that seen after VP16 treatment (Pommier et
al., 1991). How this would affect the ability of ther-
motolerant cells (via elevated hsp levels?) to become resistant
to VP16 but not m-AMSA is also as yet unclear. In any case,
the observed resistance to VP16 was not accompanied by a
reduced formation of cleavable complexes, as revealed by
PFGE analysis (Figure 5). Li (1987) also observed no altera-
tions in VM26-induced cleavable complex formation in ther-
motolerant cells. So neither drug accumulation nor drug-
DNA interaction seems to be altered in the thermotolerant
cells. This is also in accordance with hsp27-mediated protec-
tion against doxorubicin toxicity that was shown to be
unrelated to reduced drug accumulation via a multidrug-like
mechanism: immunoblot analysis revealed no P-gp 170
overexpression, and drug accumulation was unaltered by
hsp27 overexpression (Huot et al., 1991). So, as suggested by
Li (1987), the observed protection (by hsp) is likely to be at a
later stage, e.g. in DNA damage processing. In relation to
this, it is noteworthy that inducers of hsp27 phosphorylation
alone already can lead to protection against, for example,
doxorubicin and VM26 (Huot et al., 1992). Hsp27 may exert
phosphorylation-activated functions linked with growth sig-
nalling pathways (Landry et al., 1992), and as such elevated
hsp27 expression and (de)phosphorylation may alter the cell
cycle progression of the thermotolerant cells after drug treat-
ment, allowing more time for DNA damage processing. The
fact that growth arrest has been found to coincide with hsp27
phosphorylation and hsp27 levels (Spector et al., 1992) could
be in accordance with this suggestion. Alternatively, drug-
induced apoptosis might be reduced in thermotolerant cells.
In conclusion, heating cells before topoisomerase II drug
treatment protects against DNA break formation, leading to
a reduced cytotoxicity of the drugs. In cancer therapy these
treatments should therefore be used with caution. The data
indicate that the hyperthermia treatment does reduce the
ability of the drug-topoisomerase II complex to form the
cleavable complexes related to drug toxicity. Protein aggrega-
tion induced by heat may explain such an effect. Elevated
heat shock proteins may be related to the observed resistance
of thermotolerant cells to VP16 (but not m-AMSA). This
protective mechanism seems to occur at a stage after
DNA-drug interaction.
Abbreviadons: m-AMSA, 4'-(9'-acrydinylamino)methanesulphon-m-
aniside; VP16, etoposide; VM26, tenoposide; MAR, matrix-
associated region; hsp, heat shock protein; hsc, heat shock cognate;
dsb, double-strand break; PFGE, pulsed-field gelelectrophoresis.
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